Evaluation of Pharmacist-guided Digital-based Asthma Education for Indonesian Children With Asthma
Evaluation of Pharmacist-guided Digital-based Asthma Education for Indonesian Children With Asthma
Poor adherence and self-management in children with asthma results in poorly controlled asthma and increased morbidity. Pharmacists could take important roles in delivering asthma education to ensure that children can manage their disease. This study aims to evaluate the effectiveness of improving asthma control, knowledge, and quality of life. An open, randomized controlled trial will be conducted to evaluate the effectiveness of pharmacist-led digital-based asthma self-management education for children with asthma compared with paper-based asthma self-management education. Recruitment of the participants will be held at the outpatient ward of the Department of Paediatrics in 4 public hospitals in Bali Province, Indonesia, including Sanglah Public Hospital, Denpasar City; Wangaya Public Hospital, Denpasar City; Mangusada Public Hospital, Badung Regency; and Udayana University Hospital, Badung Regency. Participants will be provided with informed consent, then randomly divided into either a control group or an intervention group.
The following will be the hypotheses of the study:
Description A randomized controlled trial will be conducted in four teaching hospitals in Bali, Indonesia. The module on inhalers and asthma triggers (MIRACLE) had been developed using cultural adaptation and growth mindset elements for Indonesian children with asthma. It consists of an interactive narrative and a serious game. The intervention group will receive the MIRACLE program and written asthma plan, and the control group will receive an asthma booklet. A pharmacist will deliver the education to both groups.
Randomization and Allocation Recruited participants will be allocated to the intervention or control group on a 1:1 basis. Randomization and allocation will be conducted at each research site. Assignment numbers will be printed and sealed in opaque envelopes according to a predefined order. The envelopes will be stored in a secured cabinet. Block randomization will be performed on the basis of 2 units and random numbers will be generated using a random allocation software program by an external researcher not involved in the study. The block size will be confidential. Group assignment will be concealed until children and parents complete the consent procedures. At the time of recruitment, the researchers coordinating this study will open the numbered envelope and will allocate each participant to the control group (paper-based asthma health education) or the intervention (computer-based asthma education/the MIRACLE program) using a secured computer file. A pharmacist will administer the intervention and will be aware of the allocated groups. Due to the nature of the study, participants may be aware of the existence of the alternative group. To minimize bias, the assessors who will assess the baseline and follow-up measures will not be aware of the allocation.
Sample size calculation We will use G-Power software (version 3.1, Heinrich-Heine-Universität Düsseldorf, Germany) to calculate the estimated sample size of this study. Assuming a power of 80% with a two-sided alpha level of 0.05 to detect the difference between the intervention group and the control group, at least 36 participants were needed for each group. We will anticipate a low rate of follow-up attrition (20% dropout) and consider a sample size of 50 per group, an estimated 100 participants in total.
Study procedures Before study Before conducting the study, one pharmacist will undergo training provided by a certified asthma educator. This study will evaluate a digital-based intervention involving pharmacists in delivering patient education and counseling. A checklist form will be filled out when the pharmacist delivers asthma education to both groups.
Recruitment The recruitment process will be accompanied by pediatricians and nurses in the hospitals. Potentially eligible participants will be identified through 2 pathways: 1) first, the pediatricians will identify all children with asthma visiting the outpatient hospitals on the date of each patient's clinic visit. A research assistant will approach potential participants and will perform screening on the eligibility, then we will provide an explanatory statement, an informed consent, and a child assent form to the patients and parents. Potential participants will be asked to leave their contact details to allow one of the research assistants to contact them, or 2) second, through the electronic medical record (EMR) system in the hospitals, and then identified patients will receive a phone call, a short message, or an email. Written informed consent and child assent form from the patient and parents/guardians will be sought after the explanation procedure. Participation in this study will be voluntary and without any force to them. The subjects have the right to withdraw from the study at any time and there will be no adverse effect on their medical treatments. The reasons for not participating in patients deem ineligible or decline to participate during the follow-up session will be recorded.
Baseline visit (Time 0)
A research assistant will call all patients in advance of their clinic appointment to introduce or reintroduce the study so that they will have enough time to complete the baseline assessment, which lasts approximately 10-15 minutes. Each child will be weighed and measured as part of the polyclinic routine, then will be interviewed by the researcher as they will wait to see the pediatrician. During the assessment, the researchers will be available to answer questions and assist younger children with reading if necessary. The researchers will collect baseline measurements, including:
Intervention group A pharmacist will provide an asthma education (the MIRACLE program) for 45-60 minutes to children and parents. After face-to-face education, the pharmacist will ask patients to read the narrative and play the game. This activity will be continued at home for 7 days, and 15 minutes per day will be a minimal requirement. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan. For the control group, a pharmacist (same personnel) will provide an asthma education using a booklet for 45-60 minutes to children and parents. Patients will be asked to read the booklet at home for 15 minutes in 7 days. It mainly covered the same content as the MIRACLE program.
Follow-up (Time 1 and Time 2) Outcome measures will be collected at the baseline and at 1 and 2 months (T1 and T2) from the baseline to allow comparisons. Identical data collection forms will be used for both groups. The outcome assessors for collecting outcome data at 1 and 2 months will be masked to group allocation. They will also be prohibited to contact patients because any interaction might lead to study bias. Data collection will be ended as all participants completely finished the 2-month measurement period. One month and two months after the intervention, all of the children in the study will be visited at home, and baseline measures will be repeated (ACQ, PAQLQ, FEV1, knowledge, correct inhaler techniques, asthma experiences). Children will be asked to express their satisfaction with the digital tools. Parents will be asked to rate their child's unscheduled visits, and admissions to the hospital, and they will be asked to share their experiences with asthma.
Analysis Descriptive analysis will be undertaken to analyze the demographic characteristics as appropriate in both groups. Any difference in baseline characteristics between groups will be accounted for in the statistical analysis. The baseline characteristics of the two groups will be compared using the student's t-test for normally distributed continuous variables (mean, SD), or Mann-Whitney U test for non-normally distributed continuous variables (median, interquartile range [IQR]), and chi-square or Fischer's exact test for categorical variables (percentages). A chi-square test will be used to analyze sex, age, level of mother education, and history of asthma to determine whether significant differences existed between the two groups.
The study follows intention-to-treat analysis and a common threshold two-sided p-value (P<0.05) for statistical significance interpretation. In addition, Cohen's d for determining effect size will be calculated. Cohen's d is an effect size to indicate a standardized difference between two means with the interpretation of Cohen's d of >0.8, >0.5, and <0.2 indicating large effect, moderate effect, and poor effect, respectively. Asthma control and asthma quality of life scores at the baseline and follow-up will be compared by paired samples t-test. Correct inhaler technique before and after the intervention will be compared with Pearson's Chi-square test. We will compare the outcomes before and after the study using paired t-tests for the continuous variables and the McNemar test for the dichotomous outcomes variables. We will use Wilcoxon signed-rank tests for comparisons of nonparametric paired continuous data. Mann-Whitney tests will be used for univariate comparisons between groups for the number of emergency visits, the number of hospitalization, and the number of school absences. Statistical analysis will be performed using SPSS software (version 23.0; SPSS Inc., Chicago, IL, USA).
Missing data and dropouts Patients will be rated as dropouts when they are excluded from the study at their own request or if they are no longer able to participate in the study until the final visit. Patients who are not able to undergo all measurements during the follow-up visits will remain in the study. Multiple imputation methods will be used to impute missing data with less than 25% missing values. This is typically more efficient than a complete case analysis when covariates have missing values.
Inclusion Criteria:
Exclusion Criteria:
arysarasmita@unud.ac.id+6281703911305
shawn@tmu.edu.tw+8860227361661 ext. 6175
Badung, Bali 80116, Indonesia
ketutwidyani@unud.ac.id+6281808588717
arysarasmita@unud.ac.id+6281703911305
arysarasmita@unud.ac.id+6281703911305 ext. 0
febrayana@unud.ac.id+6285238756099 ext. 0
arysarasmita@unud.ac.id+6281703911305 ext. 0
shawn@tmu.edu.tw+8860227361661 ext. 6175
driwayansudarmaiws@gmail.com+6281703810500
arysarasmita@unud.ac.id+6281703911305